Entelos, Inc., a leader in predictive biosimulation technologies for drug discovery, development, and commercialization, has expanded its research collaboration with Johnson & Johnson Pharmaceutical Research & Development, L.L.C., to include multiple therapeutic areas over a five-year term. During the first year of this new agreement, Entelos will dedicate several teams of research engineers and life scientists to support specific projects using its PhysioLab platforms on behalf of J&JPRD and its affiliates.
J&JPRD is already using Entelos' models to validate targets, select biomarkers, and optimize clinical trials for type II diabetes, obesity, and anaemia.
"Entelos is extremely pleased to expand its long-standing relationship with J&JPRD with this broadened collaboration," James Karis, President and CEO of Entelos said adding, "From our earliest agreement signed in November 1999, J&JPRD and its affiliates recognized the value in accurately simulating human biology in silico (in a computer) to rapidly validate novel drug targets, discover biomarkers, and evaluate and develop new drugs. We believe J&JPRD's continued commitment to apply the power of biosimulation to their drug discovery and development decisions will lead to safer and more effective medicines for patients."
Entelos' teams of life scientists and engineers use its proprietary computer platforms, called PhysioLab systems, to create "virtual patients" and apply them to validate early research theories, translate preclinical data into meaningful human results, and optimize clinical trial designs in diseases such as asthma, obesity, type I and type II diabetes, and rheumatoid arthritis.